Forma Therapeutics: Novo Nordisk acquires Forma Therapeutics for $1.1bn
With the acquisition, Novo Nordisk will gain access to Forma's lead development candidate, etavopivat. The post Novo Nordisk acquires Forma Therapeutics for $1.1bn appeared first on Pharmaceutical Technology.
Read full article »
Forma Therapeutics is a Massachusetts-based biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of rare hematologic diseases.
Read more